drugset
drugset / Trial / NCT05528315

SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects

NCT05528315 ↗

Phase 1 Completed 48 enrolled Autobahn Therapeutics, Inc. Novotech (Australia) Pty Limited · collab
RandomizedSequentialTriple-blindTreatment

Summary

The study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single-ascending doses (SAD) and multiple ascending doses (MAD) of ABX-002 in healthy volunteers (HV)

Timeline

Start
2022-10-12
Primary completion
2023-06-26
Completion
2023-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject ABX-002 Small molecule — —

Indications

major depressive disorder